As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position
Cardiology, Infectious Diseases Also Remain Core Areas
Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.
